Founders

Founders operates as a co-creator rather than a reactive funder, which means deal flow is generated by actively building companies alongside operators from the earliest stage. The firm's tight sector specialization in healthtech and fintech allows its team to pursue thesis-driven origination — identifying care-model and embedded-finance gaps in Europe before they attract broad auction interest. Because the firm runs a highly concentrated book, it can spend significantly more time on each project than a generalist seed fund scanning hundreds of deals.

Founders explicitly targets companies that are pre-product and pre-market, the earliest possible institutional entry point. The firm's own language — 'Funders to Founders' and 'Hunters to Co-creators' — signals that it does not wait for traction metrics or beta products. This stage focus means Founders competes more with venture studios and super-angel syndicates than with Series A platforms.

Founders limits its investment universe to healthtech and fintech, which by construction excludes deep tech, climate, consumer marketplaces, and generalist SaaS unless they fit squarely within one of those two verticals. The firm's operating philosophy — moving from 'Quantity to Quality' — implies it has no mandate to diversify into adjacent sectors for diversification's sake. A generalist enterprise or consumer deal would fall outside its stated concentration discipline.

Founders presents itself as an asset manager making direct, earliest-stage investments and company-building partnerships, not as a fund-of-funds. Public materials describe a hands-on, co-creation model applied to individual companies, with no mention of LP commitments to third-party funds. The firm's website language — 'highly concentrated working with few companies at a time' — is incompatible with a passive fund-of-funds program.

While the firm maintains offices in Redwood City, San Francisco, Singapore, and Denmark, its investment thesis targets European healthtech and fintech. The fintech narrative is built around Europe's 1% banking-revenue penetration gap relative to the global average, and the healthtech thesis cites European healthcare spending projections to 2040. The US and Asia offices serve as operational nodes, but the deployment vehicle is overwhelmingly Europe-bound.

Founders operates with deliberate vertical depth and a self-imposed concentration limit, structurally resembling a company-builder more than a portfolio manager. Where generalist firms spread capital across dozens of sectors, Founders stays inside healthtech and fintech and makes few bets per year. Its vocabulary — Funders to Founders, FOMO to Focus — reflects an architecture where sector specialization and low volume are the product, not a temporary fund-cycle posture.

Public materials do not name a specific investment committee, managing partner, or identifiable executives. The firm's website and primary sources describe an approach and a partnership but do not disclose which individuals write checks or serve on investment committees. This absence of named principals is unusual for an early-stage manager marketing its co-creation model to potential portfolio companies.